Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2026
Teva expands European biosimilars portfolio with launch of Ahzantive (aflibercept) biosimilar to Eylea
4 June 2026 - Teva Pharmaceutical Industries today announced the launch of Ahzantive (aflibercept), a biosimilar to Eylea, in Europe further ...
Posted by Michael Wonder on 01 Jun 2026
Samsung Bioepis launches Opuviz (aflibercept) 40 mg/mL vial across Europe, to treat ophthalmic conditions
29 May 2026 - Samsung Bioepis today announced the launch of Opuviz 40 mg/mL solution for injection in a vial, ...
Posted by Michael Wonder on 02 Feb 2026
Samsung Bioepis to launch Eylea biosimilar Opuviz in Europe
30 January 2026 - Samsung Bioepis said Friday it has reached an agreement with US based firm Regeneron and Germany’s ...
Posted by Michael Wonder on 02 Dec 2025
Samsung Bioepis announces launch of denosumab biosimilars, Obodence and Xbryk in Europe
1 December 2025 - Samsung Bioepis today announced the launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...
Posted by Michael Wonder on 09 Aug 2025
Medicines for chronic illnesses soon accessible before European authorisation
7 August 2025 - The scheme will be launched on 1 January 2026 and is expected to provide access to ...
Posted by Michael Wonder on 26 Jul 2024
Sandoz launches biosimilar Pyzchiva (ustekinumab) across Europe, to treat chronic inflammatory diseases
25 July 2024 - Pyzchiva first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130 mg vial ...
Posted by Michael Wonder on 21 Nov 2023
Sandoz launches Hyrimoz (adalimumab) high concentration formulation in Europe, aiming to improve patient care
21 November 2023 - Hyrimoz HCF to launch progressively across Europe. ...
Posted by Michael Wonder on 04 May 2023
Gene therapies are still hampered by substantial delays between approval and launch
3 May 2023 - Gene therapies hold promise for treating a wide range of diseases. Innovative companies such as bluebird bio ...
Posted by Michael Wonder on 07 Sep 2022
Rhythm Pharmaceuticals announces Imcivree (setmelanotide) granted marketing authorisation by European Commission for treatment of obesity and control of hunger in Bardet-Biedl syndrome
6 September 2022 - Setmelanotide now FDA approved and EC authorized for Bardet-Biedl syndrome. ...
Posted by Michael Wonder on 25 Aug 2022
First gene therapy for adults with severe haemophilia A, BioMarin's Roctavian (valoctocogene roxaparvovec), approved by European Commission
24 August 2022 - Maintains orphan drug designation in the EU providing 10 years of market exclusivity. ...
Posted by Michael Wonder on 11 Apr 2022
Drug makers pledge speedier European market launches to avert stricter regulation
11 April 2022 - Drug makers on Monday pledged to speed up the market launch of new drugs in underserved ...
Posted by Michael Wonder on 18 Feb 2022
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
18 February 2022 - Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions. ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
Posted by Michael Wonder on 30 Mar 2021
Karyopharm receives conditional marketing authorisation from the European Commission for Nexpovio (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed and or refractory multiple myeloma
29 March 2021 - Second European Regulatory Filing Based on Phase 3 BOSTON Data Expected by April 2021. ...
Posted by Michael Wonder on 10 Nov 2020
Mirum Pharmaceuticals broadens Expanded Access Program for maralixibat in Alagille syndrome to Europe and Australia
5 November 2020 - Maralixibat Expanded Access Program now available for patients with pruritus associated with Alagille syndrome in Australia and ...